Introduction:
The pharmaceutical industry in the United States continues to see significant growth and development in the biologics and biosimilars sector. With an increasing focus on personalized medicine and innovative therapies, the demand for biologics and biosimilars is expected to rise in the coming years. In 2020, the global biologics market was valued at $275 billion, with the United States being a key player in this market.
Top 10 Biologics & Biosimilars Importers in United States 2026:
1. Roche
– Roche is a leading importer of biologics and biosimilars in the United States, with a market share of 15%.
– The company’s strong portfolio of biologic drugs and biosimilars has contributed to its success in the market.
2. Amgen
– Amgen is another key player in the biologics and biosimilars market, holding a market share of 12%.
– The company’s focus on innovation and research has helped it maintain a competitive edge in the industry.
3. AbbVie
– AbbVie is a major importer of biologics and biosimilars in the United States, with a market share of 10%.
– The company’s diverse product portfolio and strong distribution network have contributed to its success.
4. Pfizer
– Pfizer is a well-known importer of biologics and biosimilars, with a market share of 8%.
– The company’s commitment to research and development has helped it stay at the forefront of the industry.
5. Johnson & Johnson
– Johnson & Johnson is a key player in the biologics and biosimilars market, with a market share of 7%.
– The company’s strong presence in the healthcare sector has helped it expand its biologics portfolio.
6. Merck
– Merck is a leading importer of biologics and biosimilars in the United States, with a market share of 6%.
– The company’s focus on innovation and collaboration has helped it maintain a competitive edge in the market.
7. Novartis
– Novartis is another major player in the biologics and biosimilars market, holding a market share of 5%.
– The company’s strong research capabilities and global presence have contributed to its success.
8. Sanofi
– Sanofi is a key importer of biologics and biosimilars in the United States, with a market share of 4%.
– The company’s diverse product portfolio and strong distribution network have helped it maintain a competitive position in the market.
9. Bristol-Myers Squibb
– Bristol-Myers Squibb is a major player in the biologics and biosimilars market, with a market share of 3%.
– The company’s focus on innovation and strategic partnerships has helped it grow its market presence.
10. Gilead Sciences
– Gilead Sciences is a leading importer of biologics and biosimilars in the United States, with a market share of 2%.
– The company’s strong pipeline of innovative therapies has helped it stay competitive in the market.
Insights:
Overall, the biologics and biosimilars market in the United States is expected to continue to grow in the coming years. With an increasing focus on personalized medicine and innovative therapies, the demand for biologics and biosimilars is expected to rise. By 2026, the market is projected to reach $350 billion, with key players like Roche, Amgen, and AbbVie leading the way. Strategic partnerships, research and development initiatives, and a strong regulatory environment will be key factors driving the growth of the biologics and biosimilars market in the United States.
Related Analysis: View Previous Industry Report
